Shares of China's CanSino Biologics rise as much as 15% on W...
Shares of China's CanSino Biologics rise as much as 15% on Wednesday afternoon.
Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable.
康希諾生物日內走高，一度漲超15%，此前宣佈與Aerogen合作開發全球首款吸入式新冠疫苗。Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable.
免責聲明：社區由Moomoo Technologies Inc.提供，僅用於教育目的。
更多信息
評論
登錄發表評論
